肿瘤细胞治疗研究
DISEASE HUB
FOR TREATMENT
按「中国试验优先 → 正在招募 → 更新更近」排序。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性，以登记原文和主治医生判断为准。
FOR RESEARCH
Engineered Natural Killer Cell Derived-Extracellular Vesicles: An Acellular Immunotherapy with Cytotoxic Effects in SNU-1079 Human Cholangiocarcinoma
自然杀伤（NK）细胞用于治疗胆管癌等实体瘤，一直受到细胞生产、持久性和 trafficking 方面的挑战，以及免疫抑制性肿瘤微环境中疗效降低的阻碍。
Mesenchymal stem cell‑derived exosomes loaded with 5‑Fu against cholangiocarcinoma in vitro.
与游离5 Fu组相比，5 Fu Exos组显著抑制了CCA细胞的活力（P<0.01），表明5 Fu Exos可作为CCA治疗的有效化疗药物。
Selective Internal Radiotherapy Changes the Immune Profiles of Extracellular Vesicles and Their Immune Origin in Patients with Inoperable Cholangiocar
胆管细胞癌（CCA）的发病率在全球范围内呈上升趋势。
Cholangiocarcinoma derived exosomes attenuate the anti-tumor functions of NK cells.
本研究表明，胆管癌可能通过外泌体从多方面抑制NK细胞功能，从而逃避免疫监视。
Chitosan hydrogel incorporated with bone marrow mesenchymal stem cell-derived exosomal TIMP2 to inhibit angiogenesis in cholangiocarcinoma.
该研究验证了 BMSC-Exo/CS TIMP2 在 CCA 治疗中的治疗潜力。
MEMBER ACCOUNT
登录成功会直接打开下一页。
